RavenQuest BioMed Names New Legal Counsel and Auditors
2019年12月24日 - 6:05AM
RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt:
1IT) (the “
Company” or
“
RavenQuest”), today announced that, as part of
the ongoing evolution of its corporate strategy, it has retained
Farris LLP as its legal counsel and Dale Matheson Carr-Hilton
Labonte LLP as its auditors.
RavenQuest CEO, George Robinson, stated, “from a
cannabis perspective, both Farris LLP and Dale Matheson Carr-Hilton
Labonte LLP bring the experience, perspective and expertise we are
looking for in our legal and auditing teams. In keeping with our
ongoing theme of adding advisors with a deep level of knowledge in
the cannabis space, we are very excited to bring both groups
onboard in their respective advisory capacities.”
For more information, access RavenQuest’s
investor presentation, fact sheet and videos here.
Follow
RavenQuest:TwitterInstagramFacebookLinkedIn
About RavenQuest BioMed
Inc.
RavenQuest is a diversified publicly traded
cannabis company with divisions focused upon cannabis production,
management services & consulting and specialized research &
development. RavenQuest is a licensed producer with facilities
located in Markham, Ontario and Edmonton, Alberta.
RavenQuest maintains a research partnership with
McGill University focused upon cultivar (strain) recognition, plant
stabilization and yield maximization of the cannabis plant. The
Company also focuses on partnerships with Indigenous
communities.
On Behalf of the Board of Directors
ofRAVENQUEST BIOMED INC.
“George Robinson”Chief Executive Officer
For further information, please contact: Mathieu
McDonald, Corporate Communications1-877-282-1586
Neither the Canadian Securities Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Canadian Securities Exchange) accepts
responsibility for the adequacy or accuracy of this press release,
which has been prepared by management.
Cautionary Note Regarding Forward-Looking
Statement
All statements in this press release, other than
statements of historical fact, are “forward-looking information”
with respect to the Company within the meaning of applicable
securities laws. The Company provides forward-looking statements
for the purpose of conveying information about current expectations
and plans relating to the future and readers are cautioned that
such statements may not be appropriate for other purposes. By its
nature, this information is subject to inherent risks and
uncertainties that may be general or specific and which give rise
to the possibility that expectations, forecasts, predictions,
projections or conclusions will not prove to be accurate, that
assumptions may not be correct and that objectives, strategic goals
and priorities will not be achieved. These risks and uncertainties
include but are not limited those identified and reported in the
Company’s public filings under the Company’s SEDAR profile at
www.sedar.com. Although the Company has attempted to identify
important factors that could cause actual actions, events or
results to differ materially from those described in
forward-looking information, there may be other factors that cause
actions, events or results not to be as anticipated, estimated or
intended. There can be no assurance that such information will
prove to be accurate as actual results and future events could
differ materially from those anticipated in such statements. The
Company disclaims any intention or obligation to update or revise
any forward-looking information, whether as a result of new
information, future events or otherwise unless required by law.
RavenQuest BioMed (CSE:RQB)
過去 株価チャート
から 11 2024 まで 12 2024
RavenQuest BioMed (CSE:RQB)
過去 株価チャート
から 12 2023 まで 12 2024